Top Vendors in the Synthetic Gene Circuits Market & Their Offerings with Key Developments
Company Offerings
| Companies | Headquarters | Offerings |
| Ginkgo Bioworks | Massachusetts, USA | Provides organism engineering platforms that enable large-scale cell programming and custom genetic circuit development for pharmaceutical, industrial, and agricultural applications. |
| Twist Bioscience | California, USA | Specializes in high-precision synthetic DNA manufacturing used for constructing and optimizing gene circuits for research and therapeutic use. |
| GenScript Biotech | Nanjing, China | Offers gene synthesis, molecular biology services, and genome engineering solutions supporting the design and validation of synthetic genetic systems |
| Precigen | Maryland, USA | Develops engineered cellular therapies using advanced gene control systems, particularly in oncology and rare diseases. |
| Sangamo Therapeutics | California, USA | Focuses on gene regulation and editing platforms that can be integrated into programmable therapeutic genetic circuits |
Supply Chain Analysis
R&D
- Research and development in synthetic gene circuits focuses on engineering and evaluating customized genetic components made of DNA, RNA, and proteins to program specific cellular functions. These circuits enable cells to detect signals, process information, and trigger desired responses. Continuous innovation in design tools and laboratory techniques is accelerating advancements in this field.
- Key players: Thermo Fisher Scientific, GenScript, Twist Bioscience, Synthego, and Integrated DNA Technologies.
Clinical Trials
- Clinical development of synthetic gene circuits is progressing beyond laboratory research into early-stage human trials, with a major focus on applications in cancer immunotherapy and inherited metabolic disorders. These studies aim to evaluate the safety, precision, and therapeutic effectiveness of engineered cellular systems in real patients, marking an important transition toward clinical translation and commercialization.
- Key players: Sangamo Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Bluebird Bio.
Patient Support and Services
- Patient support services related to synthetic gene circuits are still developing and are mainly centered on enabling personalized, highly targeted, and adaptive treatment approaches rather than routine, established care models. Efforts focus on patient monitoring, therapy customization, and education as advanced genetic therapies move closer to broader clinical use.
- Key players: Novartis, Roche, Pfizer, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals.
Market Growth
The global synthetic gene circuits market size was estimated at USD 1.8 billion in 2025 and is predicted to increase from USD 2.06 billion in 2026 to approximately USD 1.8 billion by 2035, expanding at a CAGR of 14.55% from 2026 to 2035.
What are the Recent Developments in Synthetic Gene Circuits Market?
- In May 2025, Twist Bioscience and Ginkgo Bioworks revised their partnership agreement. Under the updated terms, Twist secured licensing rights for long DNA technology, while Ginkgo maintained flexibility to continue purchasing DNA products without any fixed minimum order requirement.
- In January 2024, Twist Bioscience broadened its Express Genes service by adding midiprep and maxiprep DNA formats. This expansion enables quicker production of larger DNA quantities, helping biotechnology companies and research institutions accelerate large-scale synthetic gene circuit development and experimental workflows.
Access a sample report of the Synthetic Gene Circuits Market customized to fit your plans; Download Now
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
